HGH Fragment 176-191

FDA describes AOD-9604 as a modified growth-hormone fragment with an added tyrosine. A product labeled only “HGH fragment 176–191” cannot be assumed to match the chemically characterized AOD-9604 preparation or inherit its clinical evidence.^[1]

• This is an applicability limitation: shorthand product names alone cannot establish molecular equivalence.
• The source document itself is not fully internally consistent about the tyrosine's location: pp. 7 and 11 both state 'N-terminal end' while a pharmacology section on p. 28 states 'C-terminal'. This claim follows the twice-repeated pp. 7/11 wording; the discrepancy is preserved here rather than silently resolved. See peptide-hgh-fragment-176-191-identity-1 for independent analytical confirmation that AOD-9604 and hGH fragment 176-191 are treated as distinct, separately detectable molecules.

A 2026 anti-doping mass-spectrometry method validated AOD9604 and hGH fragment 176-191 as separate, independently detectable analytes within a 54-compound panel in blood matrices. This analytical work treats them as distinct molecules for detection purposes; it does not test human safety, efficacy or dosing of either, and it does not establish the identity or purity of any specific vendor's research product sold under either name.^[2]

• This is a doping-control detection-method study in spiked blood matrices, not a clinical or pharmacological study; it cannot establish effects or safety of either compound in humans.
• It confirms only that the two names correspond to analytically distinguishable substances in this method, not the composition of any particular commercial product labeled with either name.
• Only the indexed abstract was inspected; full methods and tables were not reviewed.